



Post Authorisation Assessments

Versifel FeLV Suspension for Injection for Cats Vm 60021/3043

17 February 2026	To add an already authorised site for biological testing of the active substance to the manufacturing flow chart. To add an already authorised site for Physical/Chemical testing of the finished product to the manufacturing flow chart.
13 March 2025	Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV). Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in this Annex.
14 January 2025	Change of MAH from: Zoetis UK Limited, 1st Floor, Birchwood Building, Springfield Drive, Leatherhead, Surrey, KT22 7LP to Zoetis Belgium S.A., 2nd Floor, Building 10, Cherrywood Business Park, Loughlinstown, Dublin 18, D18 T3Y1, Ireland.
06 March 2024	Alignment of the SPC/QRD text with the newest EU version 9.0 QRD template and GB National SPC/QRD.
14 April 2023	The scope of this variation is the replacement of the capture and indicator antibody reagents for the FeLV antigen quantification ELISA test. Replacement of the batch used as reference standard in the FeLV antigen quantification ELISA test.
27 November 2019	Replacement of a test procedure for an excipient.
25 October 2019	Change in the address of the marketing authorisation holder from Zoetis UK Limited, 5th Floor, 6 St. Andrew Street, London, EC4A 3AE to Zoetis UK Limited, 1st Floor, Birchwood Building, Springfield Drive, Leatherhead, Surrey, KT22 7LP.
13 February 2019	Changes to a test procedure for the finished product.
25 September 2018	Change in the contact details of the QPPV of an existing pharmacovigilance system as described in the DDPS.
05 May 2016	Change of test procedure for the finished product.
27 January 2016	Renewal UK as CMS
30 April 2015	Change in the QPPV contact details.
25 April 2014	Changes to the manufacturing process of the active substance.
09 October 2013	Change of MAH in Austria, Belgium, France and Luxembourg only.
08 August 2013	Change to the contact details for the QPPV of an existing pharmacovigilance system as described in the DDPS. Change in name of the manufacturer of the finished

	<p>product including manufacturer responsible for batch release.</p> <p>Change in the name of the manufacturer of active substance used in the manufacture of the active substance where no Ph. Eur. Certificate of Suitability is part of the approved dossier.</p> <p>Change in legal entity.</p> <p>Change in distributor details.</p>
22 May 2013	Extended the shelf life of the Veterinary Medicinal Product as packaged for sale from 18 months to 2 years.
20 March 2013	Minor changes to the potency test procedure for the finished product.